Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/Day and 6 mg/Day in Patients With Acute Psychotic Episode of Schizophrenia
NCT05168007 is registered in ClinicalTrials.gov with Whanin Pharmaceutical Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/Day and 6 mg/Day in Patients With Acute Psychotic Episode of Schizophrenia
- Lead sponsor
- Whanin Pharmaceutical Company
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- November 19, 2021
- Completion date
- July 31, 2023
- Enrollment
- 342 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.